西部中医药
西部中醫藥
서부중의약
GANSU JOURNAL OF TRADITIONAL CHINESE MEDICINE
2014年
7期
84-86
,共3页
乙型肝炎,肝硬化%肝纤维化%恩替卡韦片%复方鳖甲软肝片
乙型肝炎,肝硬化%肝纖維化%恩替卡韋片%複方鱉甲軟肝片
을형간염,간경화%간섬유화%은체잡위편%복방별갑연간편
liver cirrhosis of hepatitis B%liver fibrosis%entecavir%compoundBieJiaRuanGantablets
目的：观察恩替卡韦联合复方鳖甲软肝片治疗代偿期乙肝肝硬化临床疗效。方法：将56例乙肝肝硬化代偿期患者随机分为恩替卡韦与复方鳖甲软肝片联合治疗组及恩替卡韦单药组，分别于治疗前和治疗后48周检测肝功能、HBV-DNA、血清肝纤维化指标及肝脏瞬时弹性成像测定。结果：2组患者治疗后肝功能好转、HBV-DNA水平下降，2组比较无明显差异（P＞0.05），但联合治疗组肝纤维化程度改善更明显（P＜0.05）。结论：恩替卡韦与复方鳖甲软肝片联合治疗在抗纤维化程度方面优于单用恩替卡韦。
目的：觀察恩替卡韋聯閤複方鱉甲軟肝片治療代償期乙肝肝硬化臨床療效。方法：將56例乙肝肝硬化代償期患者隨機分為恩替卡韋與複方鱉甲軟肝片聯閤治療組及恩替卡韋單藥組，分彆于治療前和治療後48週檢測肝功能、HBV-DNA、血清肝纖維化指標及肝髒瞬時彈性成像測定。結果：2組患者治療後肝功能好轉、HBV-DNA水平下降，2組比較無明顯差異（P＞0.05），但聯閤治療組肝纖維化程度改善更明顯（P＜0.05）。結論：恩替卡韋與複方鱉甲軟肝片聯閤治療在抗纖維化程度方麵優于單用恩替卡韋。
목적：관찰은체잡위연합복방별갑연간편치료대상기을간간경화림상료효。방법：장56례을간간경화대상기환자수궤분위은체잡위여복방별갑연간편연합치료조급은체잡위단약조，분별우치료전화치료후48주검측간공능、HBV-DNA、혈청간섬유화지표급간장순시탄성성상측정。결과：2조환자치료후간공능호전、HBV-DNA수평하강，2조비교무명현차이（P＞0.05），단연합치료조간섬유화정도개선경명현（P＜0.05）。결론：은체잡위여복방별갑연간편연합치료재항섬유화정도방면우우단용은체잡위。
Objective: To explore curative effects of entecavir and compoundBieJiaRuanGantablets in treat-ing decompensated liver cirrhosis of hepatitis B. Methods: All 56 patients were randomized into 29 cases of the treat-ment group and 27 cases of the control group, liver function, HBV-DNA, the indexes of liver fibrosis in the serum and liver fibroScan were detected before treating and in 48 weeks after treating. Results: After treating, liver func-tions were improved, the levels of HBV-DNA were decreased in both groups, there was no significant difference (P>0.05); the improvements of liver fibrosis in the treatment group were more remarkable (P<0.05). Conclusion: Curative effects of entecavir and compoundBieJiaRuanGantablets are superior to the effects of entecavir in treating fibrosis.
